drugset / Trial / NCT01728753

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

NCT01728753

Phase 1/2 Completed 550 enrolled MDVI, LLC United States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is safety and pharmacokinetics (PK) of favipiravir study in adults 18-80 years of age diagnosed with uncomplicated influenza.

Timeline

Start
2012-11
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Favipiravir Small molecule 600 mg Oral
Subject Favipiravir Small molecule 800 mg Oral

Indications